Systematic reviews on selected pharmacogenetic tests for cancer treatment: CYP2D6 for Tamoxifen in breast cancer, KRAS for anti-EGFR antibodies in colorectal cancer, and BCR-ABL1 for tyrosine kinase inhibitors in chronic myeloid leukemia
Terasawa T, Dahabreh I, Castaldi PJ, Trikalinos TA
Record ID 32010001448
English
Details
Project Status:
Completed
URL for project:
http://www.cms.gov/DeterminationProcess/downloads/id76TA.pdf
Year Published:
2010
URL for published report:
http://www.ahrq.gov/clinic/ta/comments/pharmgentests/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Breast Neoplasms
- Colorectal Neoplasms
- Genetic Testing
- Leukemia, Myeloid, Acute
- Predictive Value of Tests
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.